These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 14711082)

  • 1. Pharmacodynamics and clinical use of anti-HIV drugs.
    Preston SL; Piliero PJ; Drusano GL
    Infect Dis Clin North Am; 2003 Sep; 17(3):651-74. PubMed ID: 14711082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring in HIV infection: current status and future directions.
    Back D; Gatti G; Fletcher C; Garaffo R; Haubrich R; Hoetelmans R; Kurowski M; Luber A; Merry C; Perno CF
    AIDS; 2002 Mar; 16 Suppl 1():S5-37. PubMed ID: 12035820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.
    Huisman MT; Smit JW; Schinkel AH
    AIDS; 2000 Feb; 14(3):237-42. PubMed ID: 10716499
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic management of HIV.
    Johnson D
    Oral Dis; 2002; 8 Suppl 2():17-20. PubMed ID: 12164653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ups and downs of drug levels: a PK primer.
    Munk B
    GMHC Treat Issues; 2001; 15(7-8):8-11. PubMed ID: 11548511
    [No Abstract]   [Full Text] [Related]  

  • 7. Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules.
    Hoggard PG; Back DJ
    Curr Opin Infect Dis; 2002 Feb; 15(1):3-8. PubMed ID: 11964899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplifying drug regimens.
    HIV Hotline; 1998 Mar; 8(1):11. PubMed ID: 11365353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
    Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
    J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.
    Yeni PG; Hammer SM; Carpenter CC; Cooper DA; Fischl MA; Gatell JM; Gazzard BG; Hirsch MS; Jacobsen DM; Katzenstein DA; Montaner JS; Richman DD; Saag MS; Schechter M; Schooley RT; Thompson MA; Vella S; Volberding PA
    JAMA; 2002 Jul; 288(2):222-35. PubMed ID: 12095387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies.
    Taburet AM; Paci-Bonaventure S; Peytavin G; Molina JM
    Clin Pharmacokinet; 2003; 42(14):1179-91. PubMed ID: 14606928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?
    Aarnoutse RE; Schapiro JM; Boucher CA; Hekster YA; Burger DM
    Drugs; 2003; 63(8):741-53. PubMed ID: 12662123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saquinavir: a review of its use in boosted regimens for treating HIV infection.
    Plosker GL; Scott LJ
    Drugs; 2003; 63(12):1299-324. PubMed ID: 12790697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
    Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children.
    Hoody DW; Fletcher CV
    Semin Pediatr Infect Dis; 2003 Oct; 14(4):286-94. PubMed ID: 14724793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV protease inhibitors: recent clinical trials and recommendations on use.
    Fernández-Montero JV; Barreiro P; Soriano V
    Expert Opin Pharmacother; 2009 Jul; 10(10):1615-29. PubMed ID: 19527188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
    Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
    Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New HIV-1 protease inhibitors in development].
    Yoshimura K; Maeda K
    Nihon Rinsho; 2002 Apr; 60(4):780-3. PubMed ID: 11968788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.